SI-BONE, Inc. (NASDAQ:SIBN) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP cut its stake in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 50.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 504,687 shares of the company's stock after selling 523,551 shares during the quarter. Wellington Management Group LLP owned about 1.19% of SI-BONE worth $7,076,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Virtus Fund Advisers LLC purchased a new stake in shares of SI-BONE in the 4th quarter worth about $40,000. Mainstream Capital Management LLC purchased a new stake in shares of SI-BONE in the 4th quarter worth about $53,000. KLP Kapitalforvaltning AS purchased a new stake in shares of SI-BONE in the 4th quarter worth about $97,000. Proficio Capital Partners LLC purchased a new stake in shares of SI-BONE in the 4th quarter worth about $155,000. Finally, ProShare Advisors LLC purchased a new stake in shares of SI-BONE in the 4th quarter worth about $163,000. 98.11% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SIBN has been the topic of a number of recent research reports. Needham & Company LLC restated a "buy" rating and issued a $24.00 target price on shares of SI-BONE in a report on Tuesday, May 6th. Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 target price on shares of SI-BONE in a report on Tuesday, May 6th. Finally, Truist Financial upped their target price on shares of SI-BONE from $20.00 to $22.00 and gave the company a "buy" rating in a report on Tuesday, May 6th.

SI-BONE Trading Down 0.8%

Shares of SIBN stock traded down $0.16 during trading hours on Friday, hitting $18.90. 485,058 shares of the company were exchanged, compared to its average volume of 383,448. SI-BONE, Inc. has a 1 year low of $11.70 and a 1 year high of $20.05. The firm has a fifty day moving average of $16.10 and a 200 day moving average of $15.52. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The firm has a market cap of $805.42 million, a PE ratio of -20.54 and a beta of 0.82.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The firm had revenue of $47.29 million for the quarter, compared to analyst estimates of $45.13 million. Analysts expect that SI-BONE, Inc. will post -0.78 earnings per share for the current year.

Insider Activity at SI-BONE

In other news, Director Jeffrey W. Dunn sold 3,377 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $19.05, for a total transaction of $64,331.85. Following the completion of the sale, the director now owns 17,354 shares of the company's stock, valued at approximately $330,593.70. This trade represents a 16.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Michael A. Pisetsky sold 3,128 shares of the firm's stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $14.14, for a total transaction of $44,229.92. Following the sale, the senior vice president now directly owns 244,878 shares of the company's stock, valued at $3,462,574.92. The trade was a 1.26% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 95,942 shares of company stock worth $1,734,203. Company insiders own 4.00% of the company's stock.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.